Table 2. Candidates for IHC analysis, derived by correlation of expression array data with CGH and array CGH data.

Genea	Gene namea; alias	Chromosomal location	CGHb (n=145), gains	Array CGHc (n=16), gains	Expression array meta-analysisd (n=61), rank no.e
NME1	Non-metastatic cells 1, protein (NM23a) expressed in	17q21.3	15.2%	2/16	1
FASN	Fatty acid synthase; FAS, OA-519	17q25	20.7%	3/16	6
MYC	v-myc myelocytomatosis viral oncogene homolog (avian)	8q24.12–q24.13	15.2%	0/16	46
ADRBK1	Adrenergic, beta, receptor kinase 1; GRK2; BARK1	11q13	8.3%	3/16	131
PPP1CA	Protein phosphatase 1, catalytic subunit, alpha isoform	11q13	8.3%	3/16	236
			Deletions	Deletions
PPP2CB	Protein phosphatase 2 (formerly 2A), catalytic subunit, beta isoform	8p12–p11.2	23.5%	5/16	66

CGH=comparative genomic hybridisation; IHC=immunohistochemistry.

^aHUGO approved gene symbol and name.

^bAlers et al (2001), Sattler et al (1999), Steiner et al (2002), Verdorfer et al (2001), Wolter et al (2002) and Zitzelsberger et al (2001).

^cParis et al (2003).

^dRhodes et al (2002).

^eRank in lists of the 500 most upregulated and downregulated genes in prostate cancer vs benign prostate tissue.